###begin article-title 0
JNK1 is not essential for TNF-mediated joint disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.
###end p 1
###begin p 2
###xml 243 251 243 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 453 457 449 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 457 460 453 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 477 479 473 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 519 523 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 523 526 519 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 536 540 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 540 543 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 717 721 713 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 721 724 717 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 991 995 987 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 995 998 991 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1235 1239 1231 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 1239 1242 1235 1238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 340 345 <span type="species:ncbi:9606">Human</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
###xml 1249 1253 <span type="species:ncbi:10090">mice</span>
Tumour necrosis factor (TNF) signalling molecules are considered as promising therapeutic targets of antirheumatic therapy. Among them, mitogen-activated protein kinases are thought to be of central importance. Herein, we investigate the role in vivo of TNF-alpha signalling through c-Jun N-terminal kinase (JNK)1 in destructive arthritis. Human TNF transgenic (hTNFtg) mice, which develop inflammatory arthritis, were intercrossed with JNK1-deficient (JNK1-/-) mice. Animals (n = 35) of all four genotypes (wild-type, JNK1-/-, hTNFtg, JNK1-/-hTNFtg) were assessed for clinical and histological signs of arthritis. Clinical features of arthritis (swelling and decreased grip strength) developed equally in hTNFtg and JNK1-/-hTNFtg mice. Histological analyses revealed no differences in the quantity of synovial inflammation and bone erosions or in the cellular composition of the synovial infiltrate. Bone destruction and osteoclast formation were observed to a similar degree in hTNFtg and JNK1-/-hTNFtg animals. Moreover, cartilage damage, as indicated by proteoglycan loss in the articular cartilage, was comparable in the two strains. Intact phosphorylation of JNK and c-Jun as well as expression of JNK2 in the synovial tissue of JNK1-/-hTNFtg mice suggests that signalling through JNK2 may compensate for the deficiency in JNK1. Thus, JNK1 activation does not seem to be essential for TNF-mediated arthritis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 701 702 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 703 704 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Proinflammatory cytokines bind to their receptors on the plasma membrane and transmit the stimulatory effects to the nucleus via intracellular signalling molecules. Therefore, these cytokines are considered as promising therapeutic targets. Drugs specifically inhibiting such proteins are usually small molecules and are thought to open a new frontier in antirheumatic therapy along with newly arisen cytokine-blocking strategies. Among the many downstream molecules of cytokine signalling, mitogen-activated protein kinases (MAPKs) are of central importance in shuttling the signal of proinflammatory cytokines, such as IL-1 or tumour necrosis factor (TNF)-alpha, to their respective target tissues [1,2].
###end p 4
###begin p 5
###xml 352 353 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 354 355 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 503 504 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 614 615 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 616 617 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
Cellular activation by TNF-alpha is a critical step in chronic synovial inflammation and progressive joint destruction. This is supported by the overwhelming effects of TNF blockade, which has revolutionized the therapy of rheumatoid arthritis (RA). It inhibits both inflammation and destruction of joints, in a majority of patients suffering from RA [3-5]. The hypothesis is supported by animal models in which specific overexpression of TNF-alpha is sufficient to cause chronic destructive arthritis [6]. Increased levels of this cytokine in the synovial fluid and tissue of RA patients have also been reported [7-9]).).
###end p 5
###begin p 6
###xml 389 391 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 392 394 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 753 755 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
To design therapeutic tools that not only interfere with TNF signalling but also effectively block TNF-mediated inflammatory responses, it is essential to identify the major signalling targets of TNF in inflammatory joint disease. In fact, TNF-alpha signalling is a complex process, involving not only MAPKs but also other pathways including nuclear factor kappaB and the caspase cascade [10,11]. MAPKs are thought to be of central importance for mediating the proinflammatory effects of TNF-alpha. Interestingly, all three MAPK families - p38 protein kinase, extracellular signal-regulated kinase, and c-Jun N-terminal kinase (JNK) - are activated in the synovial membrane of RA patients, and TNF-alpha has the potential to signal through all of them [12]. Therefore, each of these different MAPKs is a possible therapeutic target.
###end p 6
###begin p 7
We investigated the role of JNK1 in TNF-mediated inflammatory joint disease. Our findings show that the JNK1 signal pathway is not essential for the development of arthritis and joint destruction.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Animals
###end title 9
###begin p 10
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 266 269 266 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 340 344 340 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 404 406 404 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 498 500 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 513 515 513 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 525 528 525 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 530 532 530 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 545 548 545 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 556 558 556 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
The heterozygous human TNF transgenic (hTNFtg) mouse (strain: tg197; background: C57/BL6) has been described previously [6]. As reported elsewhere, mice of this strain develop destructive arthritis resembling RA within 4-6 weeks of birth [6,13]. JNK1-deficient (JNK1-/-) mice were generated as previously described [14]. The hTNFtg and JNK1-/- strains were intercrossed to obtain double mutant animals. F2 generations were used and all data were generated from littermates. A total of 35 mice (wt, n = 7; hTNFtg, n = 13; JNK1-/-, n = 6; and JNK1-/-hTNFtg, n = 9) of six different breedings were studied. This study was approved by the local ethical committee pf the Medical University of Vienna.
###end p 10
###begin title 11
Clinical assessment
###end title 11
###begin p 12
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Arthritis was evaluated in a blinded manner as described in earlier reports [13]. Assessments were started when the mice were 5 weeks old and were repeated weekly. In brief, joint swelling was assessed using a clinical score graded from 0 to 3 (0, no swelling; 1, mild swelling of toes and ankle; 2, moderate swelling of toes and ankle; 3, severe swelling of toes and ankle). In addition, the grip strength of each paw was analysed on a wire 3 mm in diameter, using a score from 0 to -4 (0, normal grip strength; -1, mildly reduced grip strength; -2, moderately reduced grip strength; -3, severely reduced grip strength; -4, no grip strength at all). After cervical dislocation, the blood was withdrawn by heart puncture and the paws of all animals were dissected and preserved for histological analysis. The last evaluation was performed 10 weeks after birth.
###end p 12
###begin title 13
Histological sections and histochemistry
###end title 13
###begin p 14
###xml 24 26 24 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 39 41 39 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 55 57 55 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 70 73 70 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 81 83 81 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 541 543 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
A total of 26 mice (wt, n = 7; hTNFtg, n = 6; JNK1-/-, n = 6; and JNK1-/-hTNFtg, n = 7) were assessed histologically. Hind and front paws and right knee joints were fixed in 4.0% formalin overnight and then were decalcified in a 14% EDTA/ammonium hydroxide buffer at pH 7.2 (Sigma-Aldrich, St Louis, MO, USA) at 4degreesC until the bones were pliable. Serial paraffin sections (2 mum) were stained with H&E, or with toluidine blue for tartrate-resistant acid phosphatase (TRAP) activity. TRAP staining was performed as previously described [13]. For immunohistochemistry, deparaffinized, ethanol-dehydrated tissue sections were boiled for 2 min in 10 mM sodium citrate buffer (pH 6.0) using a 700-W microwave oven. Tissue sections were cooled to room temperature and then rinsed using detergent solution: 0.5% Tween in phosphate-buffered saline (PBS).
###end p 14
###begin p 15
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
For quantification of inflammation, areas of H-&-E-stained sections were measured (5 sections/animal). The total area of inflammation for each single animal was calculated by evaluating all digital, carpal, and tarsal joints and the right knee joint. The same H-&-E-stained sections were analysed as described above for quantification of erosions. The number of osteoclasts was counted as described above analysing TRAP-stained serial sections. Cartilage breakdown (i.e., proteoglycan loss and matrix dissolution) was measured from toluidine-blue-stained serial sections by assessing cartilage according to the method of Joosten and colleagues [15]. Total and destained cartilage areas were measured and percentages of destained areas indicating low proteoglycan content were ascertained.
###end p 15
###begin p 16
###xml 330 336 <span type="species:ncbi:9986">rabbit</span>
###xml 435 438 <span type="species:ncbi:10116">rat</span>
###xml 518 521 <span type="species:ncbi:10116">rat</span>
###xml 589 592 <span type="species:ncbi:10116">rat</span>
###xml 666 669 <span type="species:ncbi:10116">rat</span>
###xml 720 725 <span type="species:ncbi:10090">mouse</span>
###xml 822 827 <span type="species:ncbi:10090">mouse</span>
###xml 880 885 <span type="species:ncbi:10090">mouse</span>
For immunohistochemistry, dewaxed, ethanol-dehydrated tissue sections were boiled for 2 min in 10 mM sodium citrate buffer (pH 6.0) using a 700-W microwave oven, then allowed to cool to room temperature and rinsed in detergent solution (0.5% Tween in PBS) for 10 min. Tissue sections were blocked for 20 min in PBS containing 20% rabbit serum and were then incubated for 1 hour at room temperature with the following antibodies (Abs): rat monoclonal antimacrophage (F4/80) Ab (Serotec Inc, Oxford, UK); diluted 1:80), rat monoclonal anti-CD3 Ab (Novocastra, Newcastle, UK; diluted 1:100), rat monoclonal anti-CD45R/B220 Ab (Pharmingen International, Oxford, UK) and rat monoclonal antineutrophil Ab (clone7/4, Serotec), mouse monoclonal antiphosphorylated-JNK Ab (clone G7, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-JNK2 Ab (clone D2, Santa Cruz), and mouse monoclonal phospho-specific anti-c-Jun Ab (clone KM-1, Santa Cruz). The sections were rinsed, and then endogenous peroxidase was blocked with 0.3% hydrogen peroxide in Tris-buffered saline (10 mM Tris/HCl, 140 mM NaCl, pH 7.4) for 10 min. This was followed by 30 min of incubation with a biotinylated antirat IgG secondary Ab (Vector, Burlingame, CA, USA). Then, sections were incubated with the appropriate VECTASTAIN@ABC reagent (Vector) for another 30 min using 3,3'-diaminobenzidine (Sigma).
###end p 16
###begin title 17
Statistical analysis
###end title 17
###begin p 18
###xml 109 111 107 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
Data are shown as means +/- standard deviation. Group mean values were compared using a two-tailed Student's t test.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
TNF-induced clinical signs of arthritis develop independently of JNK1
###end title 20
###begin p 21
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 104 108 104 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 167 170 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 180 183 180 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 358 362 358 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 580 582 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 619 622 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 636 639 636 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 731 733 731 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 766 770 766 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 770 773 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 835 839 835 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 839 842 839 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 963 967 963 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 967 970 967 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
To study the role in vivo of JNK1 activation in TNF-mediated arthritis, we intercrossed hTNFtg with JNK1-/- mice. The offspring of all four genotypes (wt, hTNFtg, JNK1-/-, and JNK1-/-hTNFtg) were born at Mendelian frequency and were viable. To evaluate arthritis, we assessed joint swelling and grip strength weekly in all four genotypes. Neither wt nor JNK1-/- mice developed any signs of paw swelling, and both maintained normal grip strength (data not shown). In contrast, the hTNFtg animals developed joint swelling at 6 weeks of age, which increased to a maximum at week 10 (P < 0.05 in comparison with wt and JNK1-/-). In the JNK1-/-hTNFtg group, joint swelling started at age 7 weeks and increased significantly thereafter (P < 0.05 in comparison with wt and JNK1-/-). There was no significant difference between the hTNFtg and JNK1-/-hTNFtg mice at any time of the analysis (Fig. 1a). In addition, grip strength significantly decreased in both hTNFtg and JNK1-/-hTNFtg strains, but no significant difference between the two genotypes was found (Fig. 1b). Thus, overexpression of TNF-alpha induces clinical signs of arthritis also in the absence of JNK1.
###end p 21
###begin title 22
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 116 119 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Similar degrees of synovial inflammation and cellular composition of synovial inflammatory tissue in hTNFtg and JNK1-/-hTNFtg mice
###end title 22
###begin p 23
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 401 405 401 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 405 408 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 535 539 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 539 542 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 549 553 <span type="species:ncbi:10090">mice</span>
We next more closely evaluated arthritis by quantitative and qualitative histological analysis of inflammatory tissue (Fig. 2). Animals of both control groups, wt and JNK1-/-, did not show any sign of joint inflammation or destruction. In contrast, hTNFtg mice not only developed intense inflammation but also showed multiple bone erosions. Comparable destructive changes were observed in joints from JNK1-/-hTNFtg mice. Quantitative analysis of the area of synovial inflammation revealed no significant differences between hTNFtg and JNK1-/-hTNFtg mice (Fig. 3a). Similarly, quantification of erosive changes was comparable in these two genotypes (Fig. 3b). Furthermore, immunohistochemical analysis revealed similar distributions of T cells, B cells, granulocytes, and macrophages within the synovial membranes of the two genotypes (Table 1).
###end p 23
###begin title 24
Synovial osteoclast formation is not affected by the absence of JNK1
###end title 24
###begin p 25
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 300 303 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
Since JNK1 is involved in osteoclast differentiation, we wanted to know whether the absence of JNK1 influences TNF-driven osteoclast formation in the inflamed joints. Staining for the osteoclast-specific enzyme TRAP revealed numerous osteoclasts within arthritic bone erosions in both hTNFtg and JNK1-/-hTNFtg mice (Fig. 4a). Quantification of osteoclasts revealed no significant difference between the two groups (Fig. 4b), reflecting that the absence of JNK1 does not alter the progression of joint destruction in conditions of TNF overexpression.
###end p 25
###begin title 26
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 63 66 63 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Proteoglycan content is reduced in cartilage of hTNFtg and JNK1-/-/hTNFtg mice
###end title 26
###begin p 27
###xml 250 254 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 254 257 250 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 275 277 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 401 405 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 405 408 401 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 441 445 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 445 449 441 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 520 522 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
Lastly, we addressed whether the absence of JNK1 influences cartilage damage in TNF-alpha-induced arthritis. Quantitative assessment of proteoglycan loss by toluidine blue staining showed a marked reduction of proteoglycan content in both hTNFtg and JNK1-/-hTNFtg mice (Fig. 5a). But again, no significant difference in the percentage of the affected cartilage surface was detected between hTNFtg and JNK1-/-hTNFtg mice. In contrast, wt and JNK1-/- animals revealed virtually no alterations of articular cartilage (Fig. 5b). This suggests that TNF-alpha induces degradation of cartilage independently of JNK1.
###end p 27
###begin title 28
Lack of JNK1 decreases expression of phosphorylated JNK but does not affect activation of c-Jun
###end title 28
###begin p 29
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 18 21 18 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 223 227 223 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 337 339 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
Surprisingly, JNK1-/-hTNFtg mice developed destructive arthritis comparable to that of hTNFtg animals. Therefore, we assessed JNK signalling in animals of both genotypes. Histological staining of synovial membrane from JNK1-/- hTNFtg mice revealed significantly fewer cells expressing phosphorylated JNK than in hTNFtg animals (Fig. 6a; P < 0.05). The expression within the synovial membrane of JNK2 (Fig. 6b) or phosphorylated c-Jun (Fig. 6c) was similar in both groups that developed arthritis.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 550 552 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 678 680 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 824 826 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 930 932 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 924 928 <span type="species:ncbi:10090">mice</span>
In RA, cytokine-mediated cell activation leads to chronic synovial inflammation as well as bone and cartilage destruction. Evidence from basic and clinical research has established TNF-alpha as one of the major players in the pathogenesis of RA. The effects of TNF-alpha are mediated via membrane receptors which themselves activate intracellular messenger cascades, such as MAPK. JNKs are especially important, because of their ability to phosphorylate the activator protein (AP)-1 component c-Jun, making them critical regulators of transcription [16]. The JNK proteins include three different isoforms, of which JNK1 and (with even higher affinity) JNK2 phosphorylate c-Jun [17]. JNK2 is preferentially bound to c-Jun in unstimulated cells, whereas JNK1 becomes the major c-Jun-interacting kinase after cell stimulation [18]. Notably, JNK1 appears to be a key regulator of the differentiation of type 1 T helper cells in mice [19].
###end p 31
###begin p 32
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 341 343 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 344 346 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 347 349 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 506 508 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 556 558 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 751 753 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 754 756 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
Like other MAPK pathways, JNK signalling is activated in the synovial tissue of RA patients [12,20-22]. Studies with cultured synovial fibroblast-like cells from RA patients have established proinflammatory cytokines, such as TNF-alpha and IL-1, as important activators of JNK signalling, and JNK2 is the dominant isoform in synovial cells [12,20-22]. In these cells, TNF-induced phosphorylation of JNK leads to the phosphorylation of c-Jun and finally activation of the transcription factor complex AP-1 [20]. Loss of either JNK1 or JNK2 suppresses AP-1 [21]. The JNK pathway is therefore involved in the regulation of genes coding for collagenases, chemoattractants such as macrophage chemoattractant protein-1, or the adhesion molecule E-selectin [23,24].
###end p 32
###begin p 33
###xml 1142 1144 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1402 1404 1402 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 589 594 <span type="species:ncbi:9606">human</span>
###xml 734 739 <span type="species:ncbi:9606">human</span>
###xml 919 922 <span type="species:ncbi:10116">rat</span>
###xml 1241 1245 <span type="species:ncbi:10090">mice</span>
###xml 1396 1400 <span type="species:ncbi:10090">mice</span>
These data indicate that JNK1 is dispensable in TNF-mediated joint disease. Of interest, arthritis in hTNFtg mice is directly induced by overexpression of TNF, a potent trigger of the JNK pathway. Thus, it is surprising that even if disease is caused by the overexpression of a trigger of JNK-signalling, the absence of JNK1 is not essential for the development of the disease. However, the hTNFtg animal model has its limits, since it bypasses the autoimmune inductive phase, which is seen in other arthritis models such as collagen-induced arthritis or adjuvant arthritis, as well as in human disease. Thus, although these findings are relevant for TNF-mediated inflammation and connective tissue destruction, their implication for human RA should be seen with caution. Interestingly, the role of JNK has been investigated in autoimmune-based models of experimental arthritis in two outstanding studies. Treatment of rat adjuvant arthritis with SP600125, an inhibitor that affects kinase activity of both JNK1 and JNK2, was followed by a modest decrease of inflammation and paw swelling and an impressive inhibition of radiographic damage [21]. The influence of selective deletion of JNK2 was investigated in collagen-induced arthritis in mice. The severity of arthritis was even slightly increased, and histological evaluation showed a degree of synovial inflammation comparable to that in wt mice [25]. These latter findings suggest that selective inhibition of JNK2 is not effective to block destructive arthritis and raises the question whether JNK1 is a more promising target or effective inhibition of arthritis depends on the nonselective inhibition of JNK1 and JNK2. Our data extend this knowledge: the selective inhibition of JNK1 is not effective to block inflammation in TNF-driven arthritis. In fact, we show that even in the complete absence of JNK1, phosphorylation of JNK, although to a reduced amount, still occurs via engagement of JNK2. The latter is expressed in the synovial inflammatory tissue and its activation by TNF is sufficient to induce c-Jun transcription factor. Taken together, these findings from various experimental models of arthritis suggest that only the inhibition of both JNK isoforms, JNK1 and JNK2, may be a feasible approach to achieve a major blockade of synovitis and thus achieve therapeutic efficacy.
###end p 33
###begin p 34
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 217 221 217 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 278 287 278 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 601 608 601 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
Development of local bone erosions in the joints affected by chronic arthritis depends on the presence of osteoclasts [13,26]. Interestingly, JNK1 plays an important role in osteoclastogenesis. Cells derived from JNK1-/- mice revealed an impaired differentiation of osteoclasts in vitro [27]. Thus, targeting of JNK1 could have been considered as a feasible approach to protect from inflammatory joint damage. Surprisingly, however, the degree of bone erosions as well as numbers of osteoclasts was not affected by the lack of JNK1, indicating that TNF-driven osteoclastogensis is independent of JNK1 in vivo.
###end p 34
###begin p 35
###xml 285 287 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 411 413 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 667 671 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 671 674 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
In fact, matrix metalloproteinases substantially contribute to irreversible degradation of collagen. The IL-1-dependent induction of matrix metalloproteinases in chondrocytes is regulated through complex pathways including MAPKs, AP-1, and nuclear factor kappaB transcription factors [28]. Interestingly, lack of JNK2 led to a modest but significant reduction of cartilage damage in collagen-induced arthritis [25]. Therefore, we hypothesized that a reduction of cartilage damage could be expected after knocking out JNK1 in hTNFtg mice. However, much as with synovial inflammation and bone loss, no significant protection of articular cartilage has been observed in JNK1-/-hTNFtg, suggesting that JNK1 does not seem to be important in TNF-mediated cartilage destruction.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Taken together, these findings show that JNK1 is not essential for TNF-mediated joint disease. Specific inhibitors of JNK1 in mice probably work in conditions that are not primarily dependent on TNF-alpha. Moreover, an effective inhibition of synovitis and joint destruction may necessitate a combined blockade of the JNK isoforms or even additional MAPKs.
###end p 37
###begin title 38
Abbreviations
###end title 38
###begin p 39
###xml 81 86 <span type="species:ncbi:9606">human</span>
Ab = antibody; AP-1 = activator protein-1; H&E = hematoxylin and eosin; hTNFtg = human tumour necrosis factor transgenic; IL-1 = interleukin-1; JNK = c-Jun N-terminal kinase; MAPK = mitogen-activated protein kinase; PBS = phosphate-buffered saline; RA = rheumatoid arthritis; TNF = tumour necrosis factor; TRAP = tartrate-resistant acid phosphatase; wt = wild-type.
###end p 39
###begin title 40
Competing interests
###end title 40
###begin p 41
The author(s) declare that they have no competing interests.
###end p 41
###begin title 42
Authors' contributions
###end title 42
###begin p 43
MK carried out histological analyses and drafted the manuscript.
###end p 43
###begin p 44
SH, EW, and GS conceived of the study and participated in its design and coordination.
###end p 44
###begin p 45
KR carried out histological and statistical analyses.
###end p 45
###begin p 46
###xml 31 35 <span type="species:ncbi:10090">mice</span>
RR participated in breeding of mice.
###end p 46
###begin p 47
###xml 59 63 <span type="species:ncbi:10090">mice</span>
JD participated in the design of the study and breeding of mice.
###end p 47
###begin p 48
GSt coordinated immunohistological analysis.
###end p 48
###begin p 49
JS participated in the design of the study.
###end p 49
###begin p 50
All authors read and approved the final manuscript.
###end p 50
###begin title 51
Acknowledgements
###end title 51
###begin p 52
This study was supported by the START Prize of the Austrian Science Fund (G Schett) and the Center of Molecular Medicine (CeMM) of the Austrian Academy of Sciences. The Research Institute of Molecular Pathology is supported by Boehringer Ingelheim.
###end p 52
###begin article-title 53
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases
###end article-title 53
###begin article-title 54
Signal transduction networks in rheumatoid arthritis
###end article-title 54
###begin article-title 55
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
###end article-title 55
###begin article-title 56
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
###end article-title 56
###begin article-title 57
###xml 47 55 <span type="species:ncbi:9606">patients</span>
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
###end article-title 57
###begin article-title 58
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 27 32 <span type="species:ncbi:9606">human</span>
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis
###end article-title 58
###begin article-title 59
Cytokine production in culture by cells isolated from the synovial membrane
###end article-title 59
###begin article-title 60
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
###end article-title 60
###begin article-title 61
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha
###end article-title 61
###begin article-title 62
Tumor necrosis factor: an apoptosis JuNKie?
###end article-title 62
###begin article-title 63
TNF alpha mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated inhibition of the HSF1/hsp70 stress response
###end article-title 63
###begin article-title 64
Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis
###end article-title 64
###begin article-title 65
Osteoclasts are essential for TNF-alpha-mediated joint destruction
###end article-title 65
###begin article-title 66
c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation
###end article-title 66
###begin article-title 67
###xml 101 107 <span type="species:ncbi:10090">murine</span>
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis
###end article-title 67
###begin article-title 68
JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation
###end article-title 68
###begin article-title 69
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Identification of four splice variants of the mouse stress-activated protein kinase JNK/SAPK alpha-isoform
###end article-title 69
###begin article-title 70
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation
###end article-title 70
###begin article-title 71
Defective T cell differentiation in the absence of Jnk1
###end article-title 71
###begin article-title 72
Jun N-terminal kinase in rheumatoid arthritis
###end article-title 72
###begin article-title 73
C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
###end article-title 73
###begin article-title 74
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis
###end article-title 74
###begin article-title 75
Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha
###end article-title 75
###begin article-title 76
Tumor necrosis factor-alpha induces expression of monocyte chemoattractant JE via fos and jun genes in clonal osteoblastic MC3T3-E1 cells
###end article-title 76
###begin article-title 77
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 86 92 <span type="species:ncbi:10090">murine</span>
Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis
###end article-title 77
###begin article-title 78
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
###end article-title 78
###begin article-title 79
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms
###end article-title 79
###begin article-title 80
Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes
###end article-title 80
###begin title 81
Figures and Tables
###end title 81
###begin p 82
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 89 92 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 120 124 120 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 142 146 142 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 318 321 318 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Clinical course of arthritis in human tumour necrosis factor transgenic (hTNFtg) and JNK1-/-hTNFtg mice. Joint swelling (a) and grip strength (b) were assessed. No statistically significant differences between the two groups were detected. Vertical bars indicate standard deviation. Control animals (wild-type and JNK1-/-) showed no signs of arthritis (not shown). JNK, c-Jun N-terminal kinase.
###end p 82
###begin p 83
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 193 196 193 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 330 333 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
Histological assessment of synovial inflammation and joint destruction. No signs of arthritis are seen in the tarsal joints of wild-type (wt) and JNK1 (c-Jun N-terminal kinase 1) knockout (JNK1-/-) mice, whereas severe inflammation (I) and numerous erosions (E) are observed in human TNF transgenic (hTNFtg) and intercrossed (JNK1-/-hTNFtg) mice. H-&-E-stained sections; magnification 50x.
###end p 83
###begin p 84
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 256 260 256 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 273 277 273 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 141 146 <span type="species:ncbi:9606">human</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
Quantitative analysis of synovial inflammation and joint destruction. There were no differences in the extent of inflammatory tissue between human tumour necrosis factor transgenic (hTNFtg) and intercrossed (JNK1-/-hTNFtg) mice. Mean areas of inflammation (a) and erosions (b) were comparable in these two strains. Vertical bars indicate standard deviation. JNK, c-Jun N-terminal kinase.
###end p 84
###begin p 85
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 166 169 166 169 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 263 266 263 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 395 398 395 398 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
Synovial osteoclasts in human tumour necrosis factor transgenic (hTNFtg) and JNK1-/-hTNFtg mice. As demonstrated by staining with tartrate-resistant acid phosphatase (a), there are abundant osteoclasts (OC) at the site of erosions in hTNFtg and intercrossed (JNK1-/-hTNFtg) mice, which all developed arthritis (magnification 100x). The number of osteoclasts was similar in the two animal groups (b). Vertical bars indicate standard deviation. JNK, c-Jun N-terminal kinase.
###end p 85
###begin p 86
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 144 147 144 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 246 249 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 318 322 318 322 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 428 431 428 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
Evaluation of proteoglycan loss in human tumour necrosis factor transgenic (hTNFtg) and JNK1-/-hTNFtg mice. As shown by toluidine blue staining (a), arthritis leads to loss of proteoglycan (arrows) in the cartilage of hTNFtg and intercrossed JNK1-/-hTNFtg mice (magnification 100x). The area of early cartilage damage (b) was similar in the two groups with arthritis, whereas the joints of wild-type (wt) and JNK1 knockout (JNK1-/-) animals were unaffected. Vertical bars indicate standard deviation. JNK, c-Jun N-terminal kinase.
###end p 86
###begin p 87
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JNK1</italic>
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 213 216 213 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 229 232 229 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 272 275 272 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
Analysis of JNK activation in human tumour necrosis factor transgenic (hTNFtg) and JNK1-/-/hTNFtg mice. Synovial inflammatory tissue of the mice were stained with antibodies against the phosphorylated form of JNK (a), total JNK2 (b), and the phosphorylated forms of c-Jun (c). Positive cells are stained in brown (arrows; magnification 400x). Results of quantification (percentages of positive cells) are given in separate bar charts. Vertical bars indicate standard deviation. JNK, c-Jun N-terminal kinase; p-c-Jun, phosphorylated c-Jun; p-JNK, phosphorylated JNK. 1 cm = (a) 40 mum, (b, c) 30 mum.
###end p 87
###begin p 88
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Cellular composition (%) of cells infiltrating synovial tissue in two mouse strains with arthritis
###end p 88
###begin p 89
###xml 121 126 <span type="species:ncbi:9606">human</span>
Values are percentages (mean +/- standard deviation) of positive cells among total cells in the synovial tissue. hTNFtg, human tumour necrosis factor transgenic; JNK, c-Jun N-terminal kinase.
###end p 89

